Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhy combining these medicines is not the same as switching between them, and how the decision gets made
The scenario: you have heard both work, so why not use both at once?
It is a fair question. Mounjaro (tirzepatide) and semaglutide (sold as Wegovy for weight management) are the two most-discussed GLP-1 class medicines in the UK, and both have solid trial evidence behind them. When one medicine produces impressive weight loss, the instinct to combine them is understandable.
The problem is that both medicines slow gastric emptying, reduce appetite through overlapping hormonal pathways, and carry a shared gastrointestinal side-effect profile. If you are wondering whether taking Mounjaro and Wegovy together is safe or effective, the short answer is that running them simultaneously would not double the benefit, it would stack nausea, vomiting, diarrhoea and the risk of more serious complications such as pancreatitis without any evidence of added efficacy. No regulatory body has assessed the combination because no controlled trial has studied it. The MHRA licenses these medicines individually, each with its own safety profile, and neither licence covers co-administration.
If you want to compare how the two medicines differ when used separately, the Wegovy vs Mounjaro comparison on this site covers the trial data side by side.
What the trials actually show, separately, not together
The two medicines have been tested head-to-head in the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, which found that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. SURMOUNT-1, also published in the New England Journal of Medicine, reported around 20–21% average body-weight reduction at the 15mg tirzepatide dose over 72 weeks. STEP 1, the equivalent semaglutide trial, found approximately 15% average reduction at 2.4mg over 68 weeks.
Neither trial involved combining the two drugs. The comparison is between them, not a case for using both.
| Feature | Mounjaro (tirzepatide) | Wegovy injection (semaglutide 2.4mg) |
|---|---|---|
| Mechanism | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Average weight loss (pivotal trial) | ~20–21% at 15mg (SURMOUNT-1, 72 weeks) | ~15% at 2.4mg (STEP 1, 68 weeks) |
| UK licence for weight management | Yes (BMI ≥30, or ≥27 with a weight-related condition) | Yes (BMI ≥30, or ≥27 with a weight-related condition) |
| Licensed to combine with the other | No | No |
| NICE recommended for NHS use | Yes (TA1026 (from June 2025, phased) | Yes) TA875, specialist services, max 2 years |
Switching from one to the other, that is the real question most people are asking
Many people asking about taking both medicines are actually thinking about switching rather than combining. Maybe Wegovy is out of stock. Maybe results on semaglutide have plateaued. Maybe a prescriber has suggested tirzepatide as the next step.
Switching is a legitimate clinical conversation, and a different one from combining. There is a wash-out consideration, a dose-calibration question, and a medical history review involved. None of that can be self-managed. A quick habit worth building: before any switch, check that the pharmacy you plan to use is on the GPhC register at pharmacyregulation.org/registers, it takes under a minute and tells you whether the pharmacy is operating legally in the UK.
If you are weighing the cost difference between the two medicines as part of the decision, the cost comparison between Wegovy and Mounjaro sets out what private treatment typically involves. And if you have already been on Wegovy and are considering tirzepatide next, the practical switching guide at switching from Wegovy to Mounjaro is worth reading before any clinical conversation.
How a prescriber makes this decision (and what to expect from a nume consultation
At nume) sorry, at nume, every consultation is read by a real clinician, not a screening algorithm. When someone asks about switching or queries whether both medicines might be appropriate, the prescriber looks at current weight, the treatment history, any side effects already experienced, other medicines being taken, and relevant medical background. That full picture is what determines which licensed medicine is right, at which starting dose, and on what timeline.
Which of these two medicines suits you is a clinical decision, made individually, by our prescribers with you. You can read more about how that process works on the clinical team page, or explore the broader treatment options at our weight-loss overview. When you are ready to start that conversation, begin your free consultation here.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.